Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes. 2015

Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.

BACKGROUND CC chemokine ligand 17 (CCL17) and CCL22 are the functional ligands for CCR4. We previously reported that inhibitors of nuclear factor-kappa B and p38 mitogen-activated protein kinase (p38 MAPK), but not of extracellular signal-related kinase (ERK), inhibited tumor necrosis factor (TNF)-α- and interferon (IFN)-γ-induced production of CCL17 by the human keratinocyte cell line, HaCaT. Further, an inhibitor of epidermal growth factor receptor (EGFR) enhanced the CCL17 production by these keratinocytes. OBJECTIVE To identify the mechanism underlying CCL22 production by HaCaT cells. METHODS We investigated the signal transduction pathways by which TNF-α and IFN-γ stimulate HaCaT cells to produce CCL22 by adding various inhibitors. RESULTS TNF-α- and IFN-γ-induced CCL22 production was inhibited by PD98059, PD153035, Bay 11-7085, SB202190, c-Jun N-terminal kinase (JNK) inhibitor II, and Janus kinase (JAK) inhibitor 1. CONCLUSIONS Our results indicate that CCL22 production in HaCaT cells is dependent on ERK, EGFR, p38 MAPK, JNK, and JAK and is mediated by different signal pathways from those regulating CCL17 production. Altogether, our previous and present results suggest that EGFR activation represses CCL17 but enhances CCL22 production by these cells.

UI MeSH Term Description Entries

Related Publications

Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
January 2002, Critical reviews in immunology,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
December 2007, Clinical immunology (Orlando, Fla.),
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
November 2006, Cancer immunology, immunotherapy : CII,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
October 2008, Journal of immunology (Baltimore, Md. : 1950),
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
August 2023, International journal of molecular sciences,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
June 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
January 2004, The Journal of investigative dermatology,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
July 2002, International immunology,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
August 2009, Respiratory research,
Chizuko Yano, and Hidehisa Saeki, and Mayumi Komine, and Shinji Kagami, and Yuichiro Tsunemi, and Mamitaro Ohtsuki, and Hidemi Nakagawa
October 2012, Pathology international,
Copied contents to your clipboard!